Beijing Beilu Pharmaceutical Co., Ltd. Class A

Beijing Beilu Pharmaceutical Co., Ltd. Class A

SSZSE:300016
7.40
CNY
-0.25
(-3.27%)
0.30EPS
33.45P/E
5.56BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.74
0.95
1.11
1.02
1.06
1.23
1.67
1.7
1.78
1.36
1.86
2.16
2.34
2.45
Basic EPS, GAAP
0.15
0.19
0.07
0.03
0.24
0.3
0.7
0.36
0.26
0.02
-0.15
0.03
0.18
0.29
Free Cash Flow per Basic Share
0.01
- -
0.03
0.07
0.18
0.25
0.25
0.01
-0.08
0.04
-0.18
0.14
-0.12
- -
Dividend per Share
0.07
0.07
0.05
0.01
0.01
0.02
0.1
0.09
0.09
0.08
0.11
0.05
0.07
0.09
Book Value per Share
1.22
1.34
1.8
1.84
2.19
2.47
2.93
3.52
3.77
3.61
3.36
3.39
4.01
4.29
Tangible Book Value per Share
1.19
0.83
1.42
1.76
2.08
2.37
2.82
3.08
3.34
3.25
3.09
2.97
3.67
3.96
Basic Weighted Avg Shares
450
465
444
491
495
493
489
485
483
564
478
455
515
568
Sales/Revenue/Turnover
332
440
491
499
523
608
819
827
860
766
891
984
1,205
1,391
Operating Margin (%)
21.92
24.73
22.41
18.72
23.99
25.38
24.23
18.94
15.08
4.06
-0.01
6.61
8.48
12.55
Depreciation Expense
8
13
20
20
17
18
21
43
63
78
84
95
97
- -
Net Income, GAAP
66
87
33
16
119
148
342
175
126
11
-72
14
93
162
Effective Tax Rate (%)
16.3
17.38
35.6
30.19
15.44
10.37
13.69
11.41
9.86
- -
- -
- -
18.31
15.91
Profit Margin (%)
19.89
19.72
6.63
3.28
22.74
24.3
41.81
21.12
14.6
1.47
-8.06
1.39
7.69
11.68
Working Capital
387
202
470
368
422
383
425
1,008
1,021
875
838
716
802
996
LT Debt
- -
17
- -
- -
- -
- -
- -
553
476
526
600
605
251
238
Total Equity
559
667
933
902
1,069
1,207
1,451
1,892
2,086
1,923
1,786
1,829
2,417
2,661
Return on Invested Capital (%)
12
13.92
3.35
1.28
12.17
13.14
26.07
8.02
4.36
- -
- -
- -
3.23
5.77
Return on Capital (%)
11.23
12.22
4.3
1.9
12.06
12.8
25.77
9.87
6.87
- -
- -
- -
4.64
5.54
Return on Common Equity (%)
12.18
14.67
4.3
1.83
12.06
12.98
25.77
10.94
6.98
0.62
-4.19
0.82
4.72
7.75

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
307
329
214
LT Borrowings
266
238
236
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
563
582
582
Market Capitalization
5,629
4,462
5,561

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,447
1,596
1,530
Cash, Cash Equivalents & STI
800
882
790
Accounts Receivable, Net
230
220
221
Inventories
356
420
428
Total Current Liabilities
605
605
534
Payables & Accruals
- -
- -
- -
ST Debt
307
329
214
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.86%
5.97%
32.12%
Free Cash Flow
-178.6%
-416.22%
-201.09%
Net Income, GAAP
28.8%
-78.96%
579.29%
Sales/Revenue/Turnover
10.06%
8.45%
22.54%
Total Cash Common Dividend
48.11%
8.23%
79.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
208
266
256
254
984
2025
283
302
- -
333
1,205
2026
320
353
385
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.01
-0.02
0.03
2025
0.03
0.03
- -
0.09
0.18
2026
0.08
0.06
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
0.01
0.02
0.05
2025
- -
0.06
- -
0.01
0.07
2026
0.01
0.01
0.07
- -
- -

Company Description

CEO
Xu Wang
Full Time Employees
1,188
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Maples International Office Beijing BE China 100082
IPO Date
Nov 3, 2009
Business
Beijing Beilu Pharmaceutical Co., Ltd. (300016.SZ) is a China-based pharmaceutical company principally engaged in the research, development, production and sales of chemical drugs, with a leading position in contrast media. Founded in 1992 and headquartered in Beijing at No.32 Xizhimen North Street, Haidian District, the company offers a comprehensive portfolio of products including MRI gadolinium-based contrast media such as gadobutrol injection and gadopentetate dimeglumine injection; CT/X-ray iodine-containing contrast media such as iopamidol injection, iodixanol injection and iomeprol injection; central nervous system drugs including Jiuweizhenxin Granules for generalized anxiety disorder and insomnia; and endocrinology products such as glimepiride tablets and repaglinide tablets for type 2 diabetes treatment. Beilu operates production sites in Beijing's Miyun District and Hebei's Cangzhou, with geographic reach spanning China and exports to Southeast Asia, Africa, Latin America and the Middle East. In recent developments, the company completed the acquisition of Zhejiang Hichi Pharmaceutical Co., Ltd. in 2020 to secure API supply for iodine contrast agents and enhance industrial chain integration; established Luzhibao Pharmaceutical Co., Ltd. in Bozhou, Anhui in 2023 to bolster traditional Chinese medicine capabilities, holding 59 related approvals; and signed a strategic cooperation agreement with Anhui Chengqingtang Traditional Chinese Medicine Co., Ltd. in early 2025 to develop classic TCM formulations.